Sesen Bio, Inc.

Immunitas Therapeutics, Inc.

Eleven Biotherapeutics, Inc.

F. Hoffmann-la Roche Ag

Alison Tisdale

Eric Steven Furfine

Michael March Schmidt

Thomas M Barnes

David V Erbe

Alexandria Fusco

Michael Battles

Uli Bialucha

Frano Irvine

Elizabeth Scanlon

Emily Rosentrater

George Punkosdy

Grigorios Zarbis-Papastoitsis

Michael M Schmidt

The invention relates generally to anti-CD161 antibodies, pharmaceutical compositions comprising such antibodies, and methods of using such antibodies for treating disorders associated with or mediated by CD161, for example, certain cancers. In addition, the invention also relates to expression vectors and host cells for making these antibodies

Anti-CD161 antibodies and uses thereof

The invention relates generally to anti-CD161 antibodies, pharmaceutical compositions comprising such antibodies, and methods of using such antibodies for treating disorders associated with or mediated by CD161, for example, certain cancers. In addition, the invention also relates to expression vectors and host cells for making these antibodies.

Interleukin-6 (IL-6) antagonists are provided that are specific for binding to site II of IL-6. Methods of using such inhibitors to treat IL-6 related diseases, e.g., disease of the eye such as diabetic macular edema are disclosed.

IL-6 antagonists and uses thereof

Improved IL-6 antibodies are provided. Uses of the antibodies in the treatment of IL-6-related diseases, e.g., ocular diseases such as diabetic macular edema, are disclosed.

IL-6 antibodies

Interleukin 6 (IL-6) antagonists are provided that are specific for binding to site II of IL-6. Methods of using such inhibitors to treat IL-6 related diseases, e.g., disease of the eye such as diabetic macular edema are disclosed.

Growing community of inventors

Belmont, MA, United States of America

Alison Tisdale